Atorvastatin Recall Expanded, Affecting Millions of Americans
A large-scale recall of generic atorvastatin, the widely prescribed cholesterol-lowering medication, has been expanded following reports of improperly dissolving tablets, potentially reducing the drug’s effectiveness.
The recall, initially issued by Ascend Laboratories on September 19th, now includes approximately 142,000 bottles containing 90, 500, or 1,000 tablets manufactured between November 2024 and September 2025. The Food and Drug Administration (FDA) designated the recall as Class II on October 10th, indicating that use of the affected medication could result in temporary or medically reversible health consequences. Atorvastatin is the number one selling drug in the U.S., with over 115 million prescriptions filled annually.
The issue stems from the tablets failing to dissolve correctly during quality control testing, which could diminish the amount of the active ingredient absorbed by the body. Lowering LDL cholesterol with statins like atorvastatin has been shown to reduce the risk of cardiovascular events, and interruption of treatment can have serious consequences; a 2021 study showed a 12-15% increase in cardiovascular events and deaths after just six months off the medication. Patients should not discontinue use without consulting their doctor or pharmacist, but should check their prescription label for “MFG Ascend” or the NDC number 67877 to determine if their medication is affected. More information about drug recalls can be found on the FDA website.
The affected atorvastatin is manufactured by Alkem Laboratories in India, highlighting a growing trend of pharmaceutical production shifting overseas and the challenges it presents for U.S. drug oversight. Recent recalls of eye drops and potassium chloride capsules, also linked to manufacturing issues in India, underscore the need for increased international inspections and quality control measures. The FDA is now implementing laboratory spot testing of drugs entering the U.S. to address these concerns, as reported by NBC News.
The FDA continues to monitor the situation and encourages consumers to report any adverse events or concerns regarding the effectiveness of their medication.
